Incobotulinumtoxina

PBAC's latest decision on Incobotulinumtoxina: Recommended with restriction (2025). Considered for Treatment of moderate to severe spasticity of the upper limb and dynamic equinus foot deformity (lower limb spasticity) in patients with cerebral palsy aged 2 years and older.

Eligible population

Patients with cerebral palsy aged 2 years and older with moderate to severe spasticity of the upper limb and/or dynamic equinus foot deformity due to spasticity, who are ambulant, and treated by a neurologist, orthopaedic surgeon, paediatrician, rehabilitation specialist, or plastic surgeon.

Therapy area

Neurology

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Other

Comparator

botulinum toxin type A (Botox)

Economic model

Cost-minimisation

ICER note

Cost-minimisation approach; no ICER calculated.

Similar precedents

• Incobotulinumtoxin a
  similarity 0.88
• Botulinum toxin type a
  similarity 0.75
• Clostridium botulinum type a toxin-haemagglutinin complex
  similarity 0.71
• Clostridium botulinum type a toxin – haemagglutinin complex
  similarity 0.67
• Botulinum toxin type a purified neurotoxin complex
  similarity 0.66
• Baclofen
  similarity 0.59